Chitosan thermogels for local expansion and delivery of tumor-specific T lymphocytes towards enhanced cancer immunotherapies

Biomaterials

Volumn 75, Issue , 2016, Pages 237-249

  Monette, Anne ^a   Ceccaldi, Caroline ^b   Assaad, Elias ^b   Lerouge, Sophie ^b   Lapointe, Réjean ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b ÉCOLE DE TECHNOLOGIE SUPÉRIEURE   (Canada)

Author keywords

Cancer; Chitosan; Hydrogel; Immunotherapy; Injectable; T lymphocytes

Indexed keywords

BIOCOMPATIBILITY; BIOMECHANICS; CELLS; CHITIN; CHITOSAN; CYTOLOGY; DISEASES; GELATION; HYDROGELS; LYMPHOCYTES; PH; TUMORS;

CANCER; CANCER IMMUNOTHERAPY; HYDROGEN CARBONATES; IMMUNOTHERAPY; INJECTABLE; INJECTABLE HYDROGELS; PHYSICOCHEMICAL PROPERTY; TUMOR MICROENVIRONMENT;

T-CELLS;

BICARBONATE; CHITOSAN; GELLING AGENT; PHOSPHATE BUFFERED SALINE; GEL;

ARTICLE; CANCER IMMUNOTHERAPY; CELL ENCAPSULATION; CELL EXPANSION; CELL PROLIFERATION; CELL VIABILITY; GELATION; HUMAN; HUMAN CELL; HYDROGEL; OSMOLALITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PH; PHENOTYPE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; T LYMPHOCYTE; TUMOR CELL; ANIMAL; CD8+ T LYMPHOCYTE; CELL MOTION; CELL SURVIVAL; CYTOLOGY; CYTOTOXICITY; DRUG EFFECTS; FLOW KINETICS; GEL; IMMUNOLOGY; IMMUNOTHERAPY; INJECTION; KIDNEY NEOPLASMS; LYMPHOCYTE ACTIVATION; MATERIALS TESTING; PHARMACOLOGY; POROSITY; RAT; TEMPERATURE; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CHITOSAN; CYTOTOXICITY, IMMUNOLOGIC; GELS; HUMANS; IMMUNOTHERAPY; INJECTIONS; KIDNEY NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MATERIALS TESTING; PHENOTYPE; POROSITY; RATS; RHEOLOGY; TEMPERATURE;

EID: 84946434221     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.10.021     Document Type: Article

References (52)

1. Restifo N.P., Dudley M.E., Rosenberg S.A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 2012, 12:269-281.
2. Joseph R.W., Peddareddigari V.R., Liu P., Miller P.W., Overwijk W.W., Bekele N.B., et al. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2011, 17:4882-4891.
3. Wu R., Forget M.A., Chacon J., Bernatchez C., Haymaker C., Chen J.Q., et al. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J. 2012, 18:160-175.
4. Besser M.J., Shapira-Frommer R., Treves A.J., Zippel D., Itzhaki O., Schallmach E., et al. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients. J. Immunother. 2009, 32:415-423.
5. Tran K.Q., Zhou J., Durflinger K.H., Langhan M.M., Shelton T.E., Wunderlich J.R., et al. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J. Immunother. 2008, 31:742-751.
6. Goff S.L., Smith F.O., Klapper J.A., Sherry R., Wunderlich J.R., Steinberg S.M., et al. Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. J. Immunother. 2010, 33:840-847.
7. Shapira-Frommer R., Schachter J. Adoptive immunotherapy of advanced melanoma. Curr. Treat. Options Oncol. 2012, 13:340-353.
8. Prieto P.A., Durflinger K.H., Wunderlich J.R., Rosenberg S.A., Dudley M.E. Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy. J. Immunother. 2010, 33:547-556.
9. Itzhaki O., Hovav E., Ziporen Y., Levy D., Kubi A., Zikich D., et al. Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapy. J. Immunother. 2011, 34:212-220.
10. Dudley M.E., Gross C.A., Langhan M.M., Garcia M.R., Sherry R.M., Yang J.C., et al. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2010, 16:6122-6131.
11. Griffith K.D., Read E.J., Carrasquillo J.A., Carter C.S., Yang J.C., Fisher B., et al. In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. J. Natl. Cancer Inst. 1989, 81:1709-1717.
12. Fisher B., Packard B.S., Read E.J., Carrasquillo J.A., Carter C.S., Topalian S.L., et al. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 1989, 7:250-261.
13. Hershkovitz L., Schachter J., Treves A.J., Besser M.J. Focus on adoptive T cell transfer trials in melanoma. Clin. Dev. Immunol. 2010, 2010:260267.
14. Dieu-Nosjean M.C., Goc J., Giraldo N.A., Sautes-Fridman C., Fridman W.H. Tertiary lymphoid structures in cancer and beyond. Trends Immunol. 2014, 35:571-580.
15. Martinet L., Garrido I., Girard J.P. Tumor high endothelial venules (HEVs) predict lymphocyte infiltration and favorable prognosis in breast cancer. Oncoimmunology 2012, 1:789-790.
16. Dieu-Nosjean M.C., Antoine M., Danel C., Heudes D., Wislez M., Poulot V., et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2008, 26:4410-4417.
17. Goc J., Fridman W.H., Hammond S.A., Sautes-Fridman C., Dieu-Nosjean M.C. Tertiary lymphoid structures in human lung cancers, a new driver of antitumor immune responses. Oncoimmunology 2014, 3:e28976.
18. Coppola D., Nebozhyn M., Khalil F., Dai H., Yeatman T., Loboda A., et al. Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am. J. Pathol. 2011, 179:37-45.
19. Wirsing A.M., Rikardsen O.G., Steigen S.E., Uhlin-Hansen L., Hadler-Olsen E. Characterisation and prognostic value of tertiary lymphoid structures in oral squamous cell carcinoma. BMC Clin. Pathol. 2014, 14:38-48.
20. Nielsen J.S., Nelson B.H. Tumor-infiltrating B cells and T cells: working together to promote patient survival. Oncoimmunology 2012, 1:1623-1625.
21. Rhee J., Park O.K., Lee A., Yang D.H., Park K. Glycol chitosan-based fluorescent theranostic nanoagents for cancer therapy. Mar. Drugs 2014, 12:6038-6057.
22. Suh J.K., Matthew H.W. Application of chitosan-based polysaccharide biomaterials in cartilage tissue engineering: a review. Biomaterials 2000, 21:2589-2598.
23. Shukla S.K., Mishra A.K., Arotiba O.A., Mamba B.B. Chitosan-based nanomaterials: a state-of-the-art review. Int. J. Biol. Macromol. 2013, 59:46-58.
24. Chenite A., Chaput C., Wang D., Combes C., Buschmann M.D., Hoemann C.D., et al. Novel injectable neutral solutions of chitosan form biodegradable gels in situ. Biomaterials 2000, 21:2155-2161.
25. Ahmadi R., de Bruijn J.D. Biocompatibility and gelation of chitosan-glycerol phosphate hydrogels. J. Biomed. Mater. Res. Part A 2008, 86:824-832.
26. Assaad E., Maire M., Lerouge S. Injectable thermosensitive chitosan hydrogels with controlled gelation kinetics and enhanced mechanical resistance. Carbohydr. Polym. 2015, 130:87-96.
27. 3 for injectable drug delivery system. Int. J. Pharm. 2011, 414:6-15.
28. 3 to improve cytocompatibility. Polym. Polym. Compos. 2011, 19:781-787.
29. Winter H.H., Chambon F. Analysis of linear viscoelasticity of a crosslinking polymer at the gel point. J. Rheol. 1986, 30:367-382.
30. Riddell S.R., Greenberg P.D. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J. Immunol. Methods 1990, 128:189-201.
31. Klapper J.A., Thomasian A.A., Smith D.M., Gorgas G.C., Wunderlich J.R., Smith F.O., et al. Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy. J. Immunol. Methods 2009, 345:90-99.
32. Dudley M.E., Wunderlich J.R., Shelton T.E., Even J., Rosenberg S.A. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 2003, 26:332-342.
33. Pelletier S., Tanguay S., Lee S., Gunaratnam L., Arbour N., Lapointe R. TGF-alpha as a candidate tumor antigen for renal cell carcinomas. Cancer Immunol. Immunother. CII. 2009, 58:1207-1218.
34. Pisanti P., Yeatts A.B., Cardea S., Fisher J.P., Reverchon E. Tubular perfusion system culture of human mesenchymal stem cells on poly-L-lactic acid scaffolds produced using a supercritical carbon dioxide-assisted process. J. Biomed. Mater. Res. Part A 2012, 100:2563-2572.
35. Ikada Y. Challenges in tissue engineering. J. Royal Soc. 2006, 3:589-601. Interface / the Royal Society.
36. Mikos A.G., Sarakinos G., Lyman M.D., Ingber D.E., Vacanti J.P., Langer R. Prevascularization of porous biodegradable polymers. Biotechnol. Bioeng. 1993, 42:716-723.
37. Boyman O., Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 2012, 12:180-190.
38. Fridman W.H., Pages F., Sautes-Fridman C., Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 2012, 12:298-306.
39. Zhou J., Xiang Y., Yoshimura T., Chen K., Gong W., Huang J., et al. The role of chemoattractant receptors in shaping the tumor microenvironment. BioMed Res. Int. 2014, 2014:751392.
40. Gajewski T.F., Woo S.R., Zha Y., Spaapen R., Zheng Y., Corrales L., et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr. Opin. Immunol. 2013, 25:268-276.
41. Sharma R.K., Chheda Z.S., Jala V.R., Haribabu B. Regulation of cytotoxic T-Lymphocyte trafficking to tumors by chemoattractants: implications for immunotherapy. Expert Rev. Vaccin. 2015, 14:537-549.
42. Santin A.D., Ravaggi A., Bellone S., Pecorelli S., Cannon M., Parham G.P., et al. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix. Gynaecol Oncol 2001, 81:424-432.
43. Schleypen J.S., Baur N., Kammerer R., Nelson P.J., Rohrmann K., Grone E.F., et al. Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2006, 12:718-725.
44. Grabenbauer G.G., Lahmer G., Distel L., Niedobitek G. Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma. Clin. Cancer Res. Off.J. Am. Assoc. Cancer Res. 2006, 12:3355-3360.
45. Stephan S.B., Taber A.M., Jileaeva I., Pegues E.P., Sentman C.L., Stephan M.T. Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nat. Biotechnol. 2015, 33:97-101.
46. Stachowiak A.N., Irvine D.J. Inverse opal hydrogel-collagen composite scaffolds as a supportive microenvironment for immune cell migration. J. Biomed. Mater. Res. Part A 2008, 85:815-828.
47. Tsao C.T., Kievit F.M., Ravanpay A., Erickson A.E., Jensen M.C., Ellenbogen R.G., et al. Thermoreversible poly(ethylene glycol)-g-chitosan hydrogel as a therapeutic T lymphocyte depot for localized glioblastoma immunotherapy. Biomacromolecules 2014, 15:2656-2662.
48. Schor S.L., Allen T.D., Winn B. Lymphocyte migration into three-dimensional collagen matrices: a quantitative study. J. Cell Biol. 1983, 96:1089-1096.
49. Weber J.S., Mule J.J. Cancer immunotherapy meets biomaterials. Nat. Biotechnol. 2015, 33:44-45.
50. Prang P., Muller R., Eljaouhari A., Heckmann K., Kunz W., Weber T., et al. The promotion of oriented axonal regrowth in the injured spinal cord by alginate-based anisotropic capillary hydrogels. Biomaterials 2006, 27:3560-3569.
51. Ren D., Yi H., Wang W., Ma X. The enzymatic degradation and swelling properties of chitosan matrices with different degrees of N-acetylation. Carbohydr. Res. 2005, 340:2403-2410.
52. Zhang H., Neau S.H. In vitro degradation of chitosan by a commercial enzyme preparation: effect of molecular weight and degree of deacetylation. Biomaterials 2001, 22:1653-1658.